In this second power panel discussion, key thought leaders in healthcare business valuation discuss the ramifications of the recent update to the Stark regulations on business valuation practices. The panel will discuss whether many common ideas and practices need to be either modified or dropped altogether in order to meet the new regulatory definition of fair market value (FMV) under Stark. As part of the discussion, the panel will react and respond to the recent AAPCP webinar in which CMS provided clarification and context for the new Stark FMV definition.
Program Agenda
Should synergies be included in business valuations prepared under Stark FMV’s buyer-neutrality principle?
Should a hypothetical transaction be assumed for Stark FMV or should the actual transaction terms be used?
Does CMS’ explicit statements on valuation methodology impact how the three approaches to value are factored into a healthcare valuation, particularly the market approach?
Is the industry violating the Stark FMV program integrity principle of precluded reliance in its use of the guideline transaction method under the market approach?
How should projected practice losses factor into the valuation of a physician practice, given CMS’ concerns about practice losses and FMV (and commercial reasonableness)?
If new Stark FMV guidance had been established a decade earlier, how would this guidance have affected the controversy in the early 2010s about valuing physician practice assets under the cost approach when the practice had little to negative value under the income approach?
Learning Objectives
Recent changes and updates to the Stark regulations and how they will factor into business valuation practices.
BVR's Satisfaction Guarantee
Business Valuation Resources offers a 100% money-back guarantee on our training services. If you are not completely satisfied
with your experience, or have any feedback, please contact Business Valuation Resources at 1-503-479-8200 or
customerservice@bvresources.com.